Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1980 3
1981 2
1982 3
1983 1
1984 4
1985 7
1986 10
1987 11
1988 8
1989 17
1990 10
1991 7
1992 19
1993 15
1994 16
1995 21
1996 28
1997 22
1998 27
1999 44
2000 51
2001 41
2002 67
2003 64
2004 78
2005 103
2006 105
2007 142
2008 170
2009 192
2010 209
2011 279
2012 372
2013 461
2014 516
2015 622
2016 582
2017 674
2018 852
2019 923
2020 1147
2021 1234
2022 1043
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

9,190 results
Results by year
Filters applied: . Clear all
Page 1
Protective prototype-Beta and Delta-Omicron chimeric RBD-dimer vaccines against SARS-CoV-2.
Xu K, Gao P, Liu S, Lu S, Lei W, Zheng T, Liu X, Xie Y, Zhao Z, Guo S, Tang C, Yang Y, Yu W, Wang J, Zhou Y, Huang Q, Liu C, An Y, Zhang R, Han Y, Duan M, Wang S, Yang C, Wu C, Liu X, She G, Liu Y, Zhao X, Xu K, Qi J, Wu G, Peng X, Dai L, Wang P, Gao GF. Xu K, et al. Cell. 2022 Jun 23;185(13):2265-2278.e14. doi: 10.1016/j.cell.2022.04.029. Epub 2022 Apr 27. Cell. 2022. PMID: 35568034 Free PMC article.
Ultrasensitive Ribo-seq reveals translational landscapes during mammalian oocyte-to-embryo transition and pre-implantation development.
Xiong Z, Xu K, Lin Z, Kong F, Wang Q, Quan Y, Sha QQ, Li F, Zou Z, Liu L, Ji S, Chen Y, Zhang H, Fang J, Yu G, Liu B, Wang L, Wang H, Deng H, Yang X, Fan HY, Li L, Xie W. Xiong Z, et al. Among authors: xu k. Nat Cell Biol. 2022 Jun;24(6):968-980. doi: 10.1038/s41556-022-00928-6. Epub 2022 Jun 13. Nat Cell Biol. 2022. PMID: 35697785
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C.
Weiss A, Lorthiois E, Barys L, Beyer KS, Bomio-Confaglia C, Burks H, Chen X, Cui X, de Kanter R, Dharmarajan L, Fedele C, Gerspacher M, Guthy DA, Head V, Jaeger A, Núñez EJ, Kearns JD, Leblanc C, Maira SM, Murphy J, Oakman H, Ostermann N, Ottl J, Rigollier P, Roman D, Schnell C, Sedrani R, Shimizu T, Stringer R, Vaupel A, Voshol H, Wessels P, Widmer T, Wilcken R, Xu K, Zecri F, Farago AF, Cotesta S, Brachmann SM. Weiss A, et al. Among authors: xu k. Cancer Discov. 2022 Jun 2;12(6):1500-1517. doi: 10.1158/2159-8290.CD-22-0158. Cancer Discov. 2022. PMID: 35404998
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Wang Y, Cao J, Gu W, Shi M, Lan J, Yan Z, Jin L, Xia J, Ma S, Liu Y, Li H, Pan B, Chen W, Fei X, Wang C, Xie X, Yu L, Wang G, Li H, Jing G, Cheng H, Zhu F, Sun H, Sang W, Li D, Li Z, Zheng J, Xu K. Wang Y, et al. Among authors: xu k. J Clin Oncol. 2022 Jul 10;40(20):2246-2256. doi: 10.1200/JCO.21.01676. Epub 2022 Mar 25. J Clin Oncol. 2022. PMID: 35333600 Clinical Trial.
Plasmablastic myeloma progressed to plasma cell leukaemia.
Xu K, Childerhouse A, Al-Hassani A, Kyriakou C. Xu K, et al. EJHaem. 2021 Oct 30;2(4):869-870. doi: 10.1002/jha2.331. eCollection 2021 Nov. EJHaem. 2021. PMID: 35845221 Free PMC article. No abstract available.
A novel multimodal nanoplatform for targeting tumor necrosis.
Han X, Taratula O, St Lorenz A, Moses AS, Albarqi HA, Jahangiri Y, Wu Q, Xu K, Taratula O, Farsad K. Han X, et al. Among authors: xu k. RSC Adv. 2021 Sep 15;11(47):29486-29497. doi: 10.1039/d1ra05658a. eCollection 2021 Sep 1. RSC Adv. 2021. PMID: 35479549 Free PMC article.
9,190 results